Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.

Marrie RA, Walker JR, Graff LA, Patten SB, Bolton JM, Marriott JJ, Fisk JD, Hitchon C, Peschken C, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Patient Educ Couns. 2019 Apr 6. pii: S0738-3991(19)30132-6. doi: 10.1016/j.pec.2019.04.007. [Epub ahead of print]

2.

Patient-perceived risks of MS DMTs: Problems of communication and risk management?

McDonnell GV, Marriott JJ.

Neurology. 2019 Apr 2;92(14):647-648. doi: 10.1212/WNL.0000000000007230. Epub 2019 Mar 13. No abstract available.

PMID:
30867263
3.

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA, Marriott JJ, Peschken CA, Sareen J, Walker JR, Stewart SH, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Neurology. 2019 Jan 11. pii: 10.1212/WNL.0000000000006854. doi: 10.1212/WNL.0000000000006854. [Epub ahead of print]

PMID:
30635487
4.

Diabetes and anxiety adversely affect cognition in multiple sclerosis.

Marrie RA, Patel R, Figley CR, Kornelsen J, Bolton JM, Graff L, Mazerolle EL, Marriott JJ, Bernstein CN, Fisk JD; Comorbidity and Cognition in Multiple Sclerosis (CCOMS) Study Group.

Mult Scler Relat Disord. 2019 Jan;27:164-170. doi: 10.1016/j.msard.2018.10.018. Epub 2018 Oct 23.

5.

Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.

Gasim M, Bernstein CN, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Marrie RA; CIHR team “Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease”.

Mult Scler Relat Disord. 2018 Nov;26:124-156. doi: 10.1016/j.msard.2018.09.008. Epub 2018 Sep 12.

6.

Factors associated with perceived need for mental health care in multiple sclerosis.

Orr J, Bernstein CN, Graff LA, Patten SB, Bolton JM, Sareen J, Marriott JJ, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Mult Scler Relat Disord. 2018 Oct;25:179-185. doi: 10.1016/j.msard.2018.07.043. Epub 2018 Jul 29.

7.

Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study.

Marrie RA, Graff L, Walker JR, Fisk JD, Patten SB, Hitchon CA, Lix LM, Bolton J, Sareen J, Katz A, Berrigan LI, Marriott JJ, Singer A, El-Gabalawy R, Peschken CA, Zarychanski R, Bernstein CN.

JMIR Res Protoc. 2018 Jan 17;7(1):e15. doi: 10.2196/resprot.8794.

8.

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis.

Marrie RA, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott JJ, Bernstein CN.

Mult Scler Relat Disord. 2018 Feb;20:9-15. doi: 10.1016/j.msard.2017.12.007. Epub 2017 Dec 16.

9.

Validation of an algorithm to detect severe MS relapses in administrative health databases.

Marriott JJ, Chen H, Fransoo R, Marrie RA.

Mult Scler Relat Disord. 2018 Jan;19:134-139. doi: 10.1016/j.msard.2017.11.022. Epub 2017 Dec 2.

PMID:
29223870
10.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team.

N Engl J Med. 2017 Jun 1;376(22):2122-2133. doi: 10.1056/NEJMoa1608889.

11.

Screening Tools for Anxiety in People with Multiple Sclerosis: A Systematic Review.

Litster B, Fiest KM, Patten SB, Fisk JD, Walker JR, Graff LA, Bolton JM, Sareen J, Marriott JJ, Berrigan LI, Bernstein CN, Zarychanski R, Singer A, Hitchon CA, Peschken CA, Marrie RA; CIHR Team “Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease”.

Int J MS Care. 2016 Nov-Dec;18(6):273-281. doi: 10.7224/1537-2073.2016-004.

12.

Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis.

Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, Patten SB, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Singer A, Marrie RA; CIHR Team Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Mult Scler Relat Disord. 2016 Jan;5:12-26. doi: 10.1016/j.msard.2015.10.004. Epub 2015 Oct 19. Review.

13.

Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Traboulsee A, Létourneau-Guillon L, Freedman MS, O'Connor PW, Bharatha A, Chakraborty S, Girard JM, Giuliani F, Lysack JT, Marriott JJ, Metz LM, Morrow SA, Oh J, Sharma M, Vandorpe RA, Vertinsky TA, Wadhwa VS, von Riedemann S, Li DK.

Can J Neurol Sci. 2015 May;42(3):159-67. doi: 10.1017/cjn.2015.24. Epub 2015 Apr 21.

14.

Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new cases.

Vosoughi R, Marriott JJ.

Mult Scler Relat Disord. 2014 May;3(3):321-5. doi: 10.1016/j.msard.2013.12.007. Epub 2013 Dec 28. Review.

PMID:
25876469
15.

MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review.

Makhani N, Morrow SA, Fisk J, Evans C, Beland SG, Kulaga S, Kingwell E, Marriott JJ, Dykeman J, Jetté N, Pringsheim T, Wolfson C, Marrie RA, Koch MW.

Mult Scler Relat Disord. 2014 Jan;3(1):48-60. doi: 10.1016/j.msard.2013.06.015. Epub 2013 Jul 25.

PMID:
25877973
16.

Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA, Fisk JD, Evans C, Béland SG, Kulaga S, Dykeman J, Wolfson C, Koch MW, Marrie RA.

BMC Neurol. 2013 Sep 26;13:128. doi: 10.1186/1471-2377-13-128. Review.

17.

Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario.

Marriott JJ, Mamdani M, Saposnik G, Gomes T, Manno M, O'Connor PW.

Can J Neurol Sci. 2013 Jan;40(1):67-72.

PMID:
23250130
18.

Definitions of breakthrough disease and second-line agents.

Marriott JJ, O'Connor PW.

Neurol Clin. 2011 May;29(2):411-22. doi: 10.1016/j.ncl.2010.12.005. Review.

PMID:
21439450
19.

Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients.

Marriott JJ.

J Cent Nerv Syst Dis. 2011 Mar 16;3:43-50. doi: 10.4137/JCNSD.S5120. Print 2011.

20.

Lessons learned from long-term multiple sclerosis treatment trials.

Marriott JJ, O'Connor PW.

Mult Scler. 2010 Sep;16(9):1028-30. doi: 10.1177/1352458510371410. No abstract available.

PMID:
20813777
21.

Emerging therapies in relapsing-remitting multiple sclerosis.

Marriott JJ, O'Connor PW.

Rev Recent Clin Trials. 2010 Sep;5(3):179-88. Review.

PMID:
20500147
22.

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2010 May 4;74(18):1463-70. doi: 10.1212/WNL.0b013e3181dc1ae0. Review.

23.

Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy.

Fathers KE, Stone CM, Minhas K, Marriott JJ, Greenwood JD, Dumont DJ, Coomber BL.

Am J Pathol. 2005 Dec;167(6):1753-62.

Supplemental Content

Loading ...
Support Center